Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of HealthPAR-25-226
CFDA Number
93.242
Funding Instrument
Other
Funding Level
Federal
Jurisdiction
US
Cost Sharing
No
Open Date
November 22, 2024
Close Date
November 19, 2026
Posted Date
November 22, 2024
Tags
HHS-NIH11
Related Health & Human Services Grants
NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed)
National Institutes of Health
0d left
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
National Institutes of Health
0d left
HIV Prevention and Alcohol (R01 Clinical Trials Optional)
National Institutes of Health
0d left
Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03 Clinical Trial Not Allowed)
National Institutes of Health
0d left